T
20.23
0.28 (1.40%)
| Penutupan Terdahulu | 19.95 |
| Buka | 20.05 |
| Jumlah Dagangan | 1,841,624 |
| Purata Dagangan (3B) | 1,849,895 |
| Modal Pasaran | 1,796,521,088 |
| Harga / Jualan (P/S) | 7.11 |
| Harga / Buku (P/B) | 31.56 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Jul 2025 - 4 Aug 2025 |
| Margin Keuntungan | -137.90% |
| Margin Operasi (TTM) | -79.34% |
| EPS Cair (TTM) | -4.07 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 66.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 679.76% |
| Nisbah Semasa (MRQ) | 2.08 |
| Aliran Tunai Operasi (OCF TTM) | -237.48 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -228.53 M |
| Pulangan Atas Aset (ROA TTM) | -23.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -246.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Travere Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
0.4
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.38 |
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.63% |
| % Dimiliki oleh Institusi | 109.23% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 47.00 (Guggenheim, 132.33%) | Beli |
| 47.00 (Canaccord Genuity, 132.33%) | Beli | |
| Median | 37.50 (85.37%) | |
| Rendah | 23.00 (Stifel, 13.69%) | Pegang |
| Purata | 37.00 (82.90%) | |
| Jumlah | 5 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 17.46 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 16 May 2025 | 30.00 (48.29%) | Beli | 16.80 |
| 02 May 2025 | 30.00 (48.29%) | Beli | 21.15 | |
| Stifel | 02 May 2025 | 23.00 (13.69%) | Pegang | 21.15 |
| Guggenheim | 14 Apr 2025 | 47.00 (132.33%) | Beli | 14.83 |
| Canaccord Genuity | 10 Apr 2025 | 47.00 (132.33%) | Beli | 13.49 |
| B of A Securities | 01 Apr 2025 | 31.00 (53.24%) | Beli | 17.44 |
| JP Morgan | 26 Feb 2025 | 44.00 (117.50%) | Beli | 21.03 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |